Last reviewed · How we verify
Milrinone infusion
Milrinone infusion, marketed by the NICHD Neonatal Research Network, is a well-established treatment in its class. A key strength is the protection of its composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk lies in the lack of revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Milrinone infusion |
|---|---|
| Also known as | primacor |
| Sponsor | NICHD Neonatal Research Network |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage (PHASE3)
- Comparison of Milrinone and Epinephrine on TAPSE (NA)
- Milrinone in Congenital Diaphragmatic Hernia (PHASE2)
- Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
- Melatonin for Pulmonary Hypertension in Full Term Neonates (PHASE3)
- Cardiac Power Output in Cardiogenic Shock Patients (EARLY_PHASE1)
- Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial (PHASE3)
- The Intra-arterial Vasospasm Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Milrinone infusion CI brief — competitive landscape report
- Milrinone infusion updates RSS · CI watch RSS
- NICHD Neonatal Research Network portfolio CI